% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hertenstein:128768,
      author       = {A. Hertenstein$^*$ and T. Hielscher$^*$ and O. Menn$^*$ and
                      B. P. O. Wiestler$^*$ and F. Winkler$^*$ and M. Platten$^*$
                      and W. Wick$^*$ and A. Wick},
      title        = {{I}mpact of tapering and discontinuation of bevacizumab in
                      patients with progressive glioblastoma.},
      journal      = {Journal of neuro-oncology},
      volume       = {129},
      number       = {3},
      issn         = {1573-7373},
      address      = {Dordrecht [u.a.]},
      publisher    = {Springer Science + Business Media B.V},
      reportid     = {DKFZ-2017-04783},
      pages        = {533 - 539},
      year         = {2016},
      abstract     = {Bevacizumab is frequently used in patients with progressive
                      glioblastoma raising questions regarding frequency of
                      treatments, dosage, duration of therapy and the possibility
                      of tapering and discontinuation for selected patient groups.
                      We retrospectively assessed the safety and outcome of
                      tapering and discontinuation of bevacizumab therapy for
                      reasons other than disease progression and toxicity in 19
                      patients with progressive glioblastoma receiving bevacizumab
                      for at least 6 months. In 10 of the 19 patients tapering
                      bevacizumab resulted in complete discontinuation and
                      reinitiation after disease progression during halted
                      treatment. As a comparison group 33 patients with
                      bevacizumab for at least 6 months continuously dosed at
                      10 mg/kg every 2 weeks were selected. Age and Karnofsky
                      performance status at start of bevacizumab were similar in
                      both groups. Influenced by the selection process,
                      progression-free survival (PFS) and overall survival (OS)
                      were longer in the group receiving a tapered and
                      discontinued bevacizumab regimen (PFS 22.7 versus
                      11.2 months, HR 0.33, p-value = 0.01; OS 29.9 versus
                      15.5 months, HR 0.22, p-value = 0.001) with a median
                      time of discontinuation of 4.5 months (range:
                      1.9-44.2 months). Stable disease or partial response
                      according to RANO at ≥3 months was achieved in $89 \%$
                      of patients with reinitiated bevacizumab therapy after
                      discontinuation. These data indicate that tapering and
                      discontinuation of bevacizumab therapy for other reasons
                      than progression is feasible without an increased risk for
                      tumor rebound or unresponsiveness to reinitiated bevacizumab
                      therapy.},
      cin          = {G160 / C060 / G370},
      ddc          = {610},
      cid          = {I:(DE-He78)G160-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)G370-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27422128},
      doi          = {10.1007/s11060-016-2206-x},
      url          = {https://inrepo02.dkfz.de/record/128768},
}